<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606801</url>
  </required_header>
  <id_info>
    <org_study_id>HIC # 0706002768</org_study_id>
    <secondary_id>P50DA009241</secondary_id>
    <secondary_id>B Rounsaville</secondary_id>
    <nct_id>NCT00606801</nct_id>
  </id_info>
  <brief_title>Galantamine Effects on Cognitive Function in Abstinent Cocaine Users</brief_title>
  <official_title>Galantamine Effects on Cognitive Function in Abstinent Cocaine Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate galantamine's effects on cognitive performance in abstinent cocaine users.
      Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine
      esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these
      effects may result in improved cognitive performance in a group of subjects known to have
      impaired performance in various cognitive tasks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine
      users. The cognitive performance will be measured with the Stroop test and 3 Cambridge
      Neuropsychological Test Automated Battery (CANTAB) tests: Paired Associate Learning (PAL),
      Delayed Pattern Recognition Memory (PRM),and Rapid Visual Information Processing (RVIP).
      Performance on these tests has been shown to be impaired in abstinent cocaine users, compared
      to healthy controls.

      Galantamine, compared to placebo, will not be associated with any significant changes in
      mood. Monitoring of mood will be achieved with 3 mood scales: 1) Center for Epidemiologic
      Studies Depression (CES-D) scale, Positive and Negative Affect Schedule (PANAS) and the
      Profile of Mood States (POMS).

      Currently this study is completed, Patients are no longer being enrolled. There were 28
      completers. This study has been published.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance on 3 Cognitive Tests From the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP, PAL and PRM.</measure>
    <time_frame>Baseline, Day 5 and Day 10</time_frame>
    <description>Rapid Visual Processing test (RVIP) is a measure of sustained attention with a small working memory component that is sensitive to cholinergic enhancers. In the RVIP, subjects must detect either odd or even 3 digit sequences appearing in a box in a pseudo-random order at 100 digits per minute. Reaction time (RT) to correct answers, total hits, correct rejections and A' (sensitivity to target sequences) were determined. Paired Associate Learning (PAL) measures visual memory and new learning by testing a the ability to remember the initial location of a pattern after it is re-presented in the middle of the screen. Errors result in a reminder presentation of the original location. The stages completed and number of errors are measures of interest. Pattern Recognition Memory (PRM) tests visual pattern recognition memory in a two choice forced discrimination paradigm. 12 visual patterns are presented, then the subject must choose between each of these patterns and a novel pattern.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance on the Sustained Attention to Response Task (SART).</measure>
    <time_frame>Baseline, Day 5 and Day 10</time_frame>
    <description>The SART is a Go / NoGo task measuring the ability to activate or inhibit responses. Cocaine users are know to have deficits in response inhibition on such tasks. The number of errors on NoGo and Go trials, as well as the mean reaction time (RT in milliseconds) for correct responses on Go Trials were measured.
Complete data for 3 subjects in the Placebo group, and for 1 subject in the galantamine group were not capture do to experimenter and computer errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on the Modified Stroop Task (Cocaine-Stroop)</measure>
    <time_frame>Baseline, Day 5 and Day 10</time_frame>
    <description>The Cocaine-Stroop task measures attention capture (attentional bias) secondary to cocaine cues; (Stroop effect - calculated as the difference between mean RT on cocaine words and mean RT on control words). Subjects completed 2 counterbalanced blocks (150 trials per block). One block contained 15 cocaine words and neutral words in a mixed order. The other block contained 15 control words matched in length and frequency to cocaine words, and a different set of neutral words. Subjects were required to indicate the colors in which the words were written as quickly and accurately as possible. Reaction times for identification of word color was measured. In addition, the difference in RT to words following cocaine and control words were measured (carry-over effect). Complete data for 3 participants (2 placebo and 1 galantamine) were not capture due to experimenter and computer errors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cocaine Abuse</condition>
  <arm_group>
    <arm_group_label>Galantamine 8 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Galantamine 8 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Galantamine 8 mg/day</description>
    <arm_group_label>Galantamine 8 mg/day</arm_group_label>
    <other_name>Nivalin,</other_name>
    <other_name>Razadyne,</other_name>
    <other_name>Razadyne ER,</other_name>
    <other_name>Reminyl,</other_name>
    <other_name>Lycoremine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sugar pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females, between the ages 21 and 50

          -  Fulfill criteria for past cocaine dependence

          -  No cocaine use for the past 30 days

          -  No other current dependence or abuse of other drugs or alcohol

          -  No current medical problems and normal ECG

          -  Not pregnant,nor breast feeding,

          -  Using acceptable birth control methods.

        Exclusion Criteria:

          -  Current major psychiatric illness including mood, psychotic or anxiety disorders

          -  History of major medical illnesses; including asthma or chronic obstructive lung
             disease, history or current gastrointestinal ulcer, hepatic or renal impairment and
             cardiac rhythm disturbances

          -  Use of other medications including,drugs that slow heart rate

          -  Known allergy to galantamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <results_first_submitted>February 8, 2012</results_first_submitted>
  <results_first_submitted_qc>June 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2013</results_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>cognitive enhancers</keyword>
  <keyword>Nootropic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Abstinent cocaine users recruited from 2007 to 2009 using word of mouth, fliers, and newspaper advertisements. This was an outpatient study conducted in a Yale University &amp; Veteran Affairs substance abuse research clinic.</recruitment_details>
      <pre_assignment_details>55 subjects were screened. 21 subjects were excluded. (Not meeting inclusion criteria n=19, declined to participate n=2). These 34 subjects were then assigned to treatment groups. Prior to the 1st day of intervention, subjects underwent an adaptation session where they were familiarized with study procedures, and baseline measures were obtained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo given for 10 days.</description>
        </group>
        <group group_id="P2">
          <title>Galantamine 8 mg/Day</title>
          <description>Galantamine 8 mg/day given for 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Adaptation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Galantamine 8 mg/Day</title>
          <description>Galantamine 8 mg/day given for 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo given for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="5.9"/>
                    <measurement group_id="B2" value="42.7" spread="6.3"/>
                    <measurement group_id="B3" value="42.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Performance on 3 Cognitive Tests From the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP, PAL and PRM.</title>
        <description>Rapid Visual Processing test (RVIP) is a measure of sustained attention with a small working memory component that is sensitive to cholinergic enhancers. In the RVIP, subjects must detect either odd or even 3 digit sequences appearing in a box in a pseudo-random order at 100 digits per minute. Reaction time (RT) to correct answers, total hits, correct rejections and A' (sensitivity to target sequences) were determined. Paired Associate Learning (PAL) measures visual memory and new learning by testing a the ability to remember the initial location of a pattern after it is re-presented in the middle of the screen. Errors result in a reminder presentation of the original location. The stages completed and number of errors are measures of interest. Pattern Recognition Memory (PRM) tests visual pattern recognition memory in a two choice forced discrimination paradigm. 12 visual patterns are presented, then the subject must choose between each of these patterns and a novel pattern.</description>
        <time_frame>Baseline, Day 5 and Day 10</time_frame>
        <population>There were a total of 28 completers, 14 for each treatment group. However, CANTAB data was not stored on the hard drive for one subject in the Galantamine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Baseline</title>
            <description>Measures prior to medication administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Day 5</title>
            <description>Measures in placebo group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Day 10</title>
            <description>Measures in placebo group on Day 10 of medication administration.</description>
          </group>
          <group group_id="O4">
            <title>Galantamine - Baseline</title>
            <description>Measures in galantamine group prior to medication administration.</description>
          </group>
          <group group_id="O5">
            <title>Galantamine - Day 5</title>
            <description>Measures in galantamine group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O6">
            <title>Galantamine - Day 10</title>
            <description>Measures in galantamine group on Day 10 of medication administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on 3 Cognitive Tests From the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP, PAL and PRM.</title>
          <description>Rapid Visual Processing test (RVIP) is a measure of sustained attention with a small working memory component that is sensitive to cholinergic enhancers. In the RVIP, subjects must detect either odd or even 3 digit sequences appearing in a box in a pseudo-random order at 100 digits per minute. Reaction time (RT) to correct answers, total hits, correct rejections and A' (sensitivity to target sequences) were determined. Paired Associate Learning (PAL) measures visual memory and new learning by testing a the ability to remember the initial location of a pattern after it is re-presented in the middle of the screen. Errors result in a reminder presentation of the original location. The stages completed and number of errors are measures of interest. Pattern Recognition Memory (PRM) tests visual pattern recognition memory in a two choice forced discrimination paradigm. 12 visual patterns are presented, then the subject must choose between each of these patterns and a novel pattern.</description>
          <population>There were a total of 28 completers, 14 for each treatment group. However, CANTAB data was not stored on the hard drive for one subject in the Galantamine group.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean RT for correct answers on RVIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.7" spread="92.3"/>
                    <measurement group_id="O2" value="427.4" spread="35.3"/>
                    <measurement group_id="O3" value="433.3" spread="123.6"/>
                    <measurement group_id="O4" value="476.8" spread="119.3"/>
                    <measurement group_id="O5" value="379.2" spread="71.7"/>
                    <measurement group_id="O6" value="386.9" spread="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hits for RVIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="3.6"/>
                    <measurement group_id="O2" value="18.0" spread="5.0"/>
                    <measurement group_id="O3" value="18" spread="6.8"/>
                    <measurement group_id="O4" value="14.8" spread="4.7"/>
                    <measurement group_id="O5" value="16.9" spread="5.4"/>
                    <measurement group_id="O6" value="19.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Correct Rejections in RVIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.2" spread="13.7"/>
                    <measurement group_id="O2" value="247.6" spread="16.9"/>
                    <measurement group_id="O3" value="248.2" spread="23.7"/>
                    <measurement group_id="O4" value="242.4" spread="15.5"/>
                    <measurement group_id="O5" value="247.9" spread="12.9"/>
                    <measurement group_id="O6" value="253.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detection Sensitivity (A') in RVIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.04"/>
                    <measurement group_id="O2" value="0.90" spread="0.07"/>
                    <measurement group_id="O3" value="0.90" spread="0.1"/>
                    <measurement group_id="O4" value="0.87" spread="0.07"/>
                    <measurement group_id="O5" value="0.90" spread="0.07"/>
                    <measurement group_id="O6" value="0.92" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detection Strength (B&quot;) in RVIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.18"/>
                    <measurement group_id="O2" value="0.82" spread="0.22"/>
                    <measurement group_id="O3" value="0.85" spread="0.25"/>
                    <measurement group_id="O4" value="0.88" spread="0.25"/>
                    <measurement group_id="O5" value="0.91" spread="0.11"/>
                    <measurement group_id="O6" value="0.88" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL - stages completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.4"/>
                    <measurement group_id="O2" value="4.9" spread="0.4"/>
                    <measurement group_id="O3" value="4.9" spread="0.4"/>
                    <measurement group_id="O4" value="4.9" spread="0.4"/>
                    <measurement group_id="O5" value="4.9" spread="0.4"/>
                    <measurement group_id="O6" value="4.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL - Mean number of errors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="22.3"/>
                    <measurement group_id="O2" value="23.6" spread="17.7"/>
                    <measurement group_id="O3" value="17.7" spread="16.6"/>
                    <measurement group_id="O4" value="25.6" spread="16.5"/>
                    <measurement group_id="O5" value="18.1" spread="11.5"/>
                    <measurement group_id="O6" value="16.8" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRM - Mean RT for correct answers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2357" spread="526"/>
                    <measurement group_id="O2" value="2092" spread="573"/>
                    <measurement group_id="O3" value="1995" spread="479"/>
                    <measurement group_id="O4" value="2439" spread="685"/>
                    <measurement group_id="O5" value="2092" spread="522"/>
                    <measurement group_id="O6" value="1889" spread="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRM - mean number of correct answeres</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="3.2"/>
                    <measurement group_id="O2" value="14.9" spread="2.9"/>
                    <measurement group_id="O3" value="21.0" spread="2.9"/>
                    <measurement group_id="O4" value="20.2" spread="2.5"/>
                    <measurement group_id="O5" value="20.6" spread="2.5"/>
                    <measurement group_id="O6" value="20.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect, repeated-measures model using main effect terms of treatment (placebo or galantine) and time (day of measurement). Interaction of main effects were also analyzed, with a random effect for participant. Given the hypothesis generating nature of the study, values of p&lt;0.05 were considered statistically significant based on two-tailed tests. Significant interactions were followed by Bonferroni post hoc pairwise comparisons.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on the Sustained Attention to Response Task (SART).</title>
        <description>The SART is a Go / NoGo task measuring the ability to activate or inhibit responses. Cocaine users are know to have deficits in response inhibition on such tasks. The number of errors on NoGo and Go trials, as well as the mean reaction time (RT in milliseconds) for correct responses on Go Trials were measured.
Complete data for 3 subjects in the Placebo group, and for 1 subject in the galantamine group were not capture do to experimenter and computer errors.</description>
        <time_frame>Baseline, Day 5 and Day 10</time_frame>
        <population>Participants analyzed are those that completed the treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Baseline</title>
            <description>Measures in placebo group prior to medication administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Day 5</title>
            <description>Measures in placebo group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Day 10</title>
            <description>Measures in placebo group on Day 10 of medication administration.</description>
          </group>
          <group group_id="O4">
            <title>Galantamine - Baseline</title>
            <description>Measures in galantamine group prior to medication administration.</description>
          </group>
          <group group_id="O5">
            <title>Galantamine - Day 5</title>
            <description>Measures in galantamine group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O6">
            <title>Galantamine - Day 10</title>
            <description>Measures in galantamine group on Day 10 of medication administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on the Sustained Attention to Response Task (SART).</title>
          <description>The SART is a Go / NoGo task measuring the ability to activate or inhibit responses. Cocaine users are know to have deficits in response inhibition on such tasks. The number of errors on NoGo and Go trials, as well as the mean reaction time (RT in milliseconds) for correct responses on Go Trials were measured.
Complete data for 3 subjects in the Placebo group, and for 1 subject in the galantamine group were not capture do to experimenter and computer errors.</description>
          <population>Participants analyzed are those that completed the treatment phase.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SART-number of errors on NoGo trials</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="6.4"/>
                    <measurement group_id="O2" value="10.7" spread="6.5"/>
                    <measurement group_id="O3" value="11.8" spread="7.7"/>
                    <measurement group_id="O4" value="13.1" spread="5.8"/>
                    <measurement group_id="O5" value="10.2" spread="7.9"/>
                    <measurement group_id="O6" value="12.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SART-number of errors on Go trials</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="16.8"/>
                    <measurement group_id="O2" value="12.0" spread="19.1"/>
                    <measurement group_id="O3" value="10.6" spread="10.6"/>
                    <measurement group_id="O4" value="7.2" spread="7.4"/>
                    <measurement group_id="O5" value="3.8" spread="4.1"/>
                    <measurement group_id="O6" value="5.1" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SART - Mean RT for correct press on Go Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.7" spread="79.7"/>
                    <measurement group_id="O2" value="405.4" spread="81.7"/>
                    <measurement group_id="O3" value="411.1" spread="74.2"/>
                    <measurement group_id="O4" value="375.3" spread="88.5"/>
                    <measurement group_id="O5" value="382.6" spread="79.9"/>
                    <measurement group_id="O6" value="357.8" spread="109.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect, repeated-measures model using main effect terms of treatment (placebo or galantine) and time (day of measurement). Interaction of main effects were also analyzed, with a random effect for participant. Given the hypothesis generating nature of the study, values of p&lt;0.05 were considered statistically significant based on two-tailed tests. Significant interactions were followed by Bonferroni post hoc pairwise comparisons.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on the Modified Stroop Task (Cocaine-Stroop)</title>
        <description>The Cocaine-Stroop task measures attention capture (attentional bias) secondary to cocaine cues; (Stroop effect - calculated as the difference between mean RT on cocaine words and mean RT on control words). Subjects completed 2 counterbalanced blocks (150 trials per block). One block contained 15 cocaine words and neutral words in a mixed order. The other block contained 15 control words matched in length and frequency to cocaine words, and a different set of neutral words. Subjects were required to indicate the colors in which the words were written as quickly and accurately as possible. Reaction times for identification of word color was measured. In addition, the difference in RT to words following cocaine and control words were measured (carry-over effect). Complete data for 3 participants (2 placebo and 1 galantamine) were not capture due to experimenter and computer errors.</description>
        <time_frame>Baseline, Day 5 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Baseline</title>
            <description>Measures in placebo group prior to medication administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Day 5</title>
            <description>Measures in placebo group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Day 10</title>
            <description>Measures in placebo group on Day 10 of medication administration.</description>
          </group>
          <group group_id="O4">
            <title>Galantamine - Baseline</title>
            <description>Measures in galantamine group prior to medication administration.</description>
          </group>
          <group group_id="O5">
            <title>Galantamine - Day 5</title>
            <description>Measures in galantamine group on Day 5 of medication administration.</description>
          </group>
          <group group_id="O6">
            <title>Galantamine - Day 10</title>
            <description>Measures in galantamine group on Day 10 of medication administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on the Modified Stroop Task (Cocaine-Stroop)</title>
          <description>The Cocaine-Stroop task measures attention capture (attentional bias) secondary to cocaine cues; (Stroop effect - calculated as the difference between mean RT on cocaine words and mean RT on control words). Subjects completed 2 counterbalanced blocks (150 trials per block). One block contained 15 cocaine words and neutral words in a mixed order. The other block contained 15 control words matched in length and frequency to cocaine words, and a different set of neutral words. Subjects were required to indicate the colors in which the words were written as quickly and accurately as possible. Reaction times for identification of word color was measured. In addition, the difference in RT to words following cocaine and control words were measured (carry-over effect). Complete data for 3 participants (2 placebo and 1 galantamine) were not capture due to experimenter and computer errors.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reaction Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722" spread="117"/>
                    <measurement group_id="O2" value="734" spread="126"/>
                    <measurement group_id="O3" value="748" spread="159"/>
                    <measurement group_id="O4" value="771" spread="136"/>
                    <measurement group_id="O5" value="742" spread="145"/>
                    <measurement group_id="O6" value="698" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroop Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="66.2"/>
                    <measurement group_id="O2" value="-19.7" spread="87.6"/>
                    <measurement group_id="O3" value="-61.5" spread="183.9"/>
                    <measurement group_id="O4" value="-13.1" spread="137.6"/>
                    <measurement group_id="O5" value="19.6" spread="149.3"/>
                    <measurement group_id="O6" value="-33.7" spread="133.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carry-over effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="95.5"/>
                    <measurement group_id="O2" value="43.5" spread="131.2"/>
                    <measurement group_id="O3" value="-29.8" spread="179.6"/>
                    <measurement group_id="O4" value="13.4" spread="131.9"/>
                    <measurement group_id="O5" value="32.1" spread="96.2"/>
                    <measurement group_id="O6" value="18.6" spread="110.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect, repeated-measures model using main effect terms of treatment (placebo or galantine) and time (day of measurement). Interaction of main effects were also analyzed, with a random effect for participant. Given the hypothesis generating nature of the study, values of p&lt;0.05 were considered statistically significant based on two-tailed tests. Significant interactions were followed by Bonferroni post hoc pairwise comparisons.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Galantamine 8 mg/Day</title>
          <description>Galantamine 8 mg/day given for 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo given for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively low medication dose and short duration of treatment. Multiple cognitive tests and outcome measures increase probability of Type 1 errors. Absence of non-addicted controls limits determination of a unique effect in abstinent users.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mehmet Sofuoglu, M.D., Ph.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-937-4809</phone>
      <email>mehmet.sofuoglu@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

